Skip to content
Subscriber Only
Business
Prognosis

Leading Cancer Center No Longer Offering Zantac to Patients

  • Memorial Sloan Kettering researching cancer risk of the drugs
  • Health officials investigating carcinogen levels in Zantac
Zantac
Photographer: Drew Angerer/Getty Images

One of the nation’s leading cancer centers will no longer offer Zantac and its generics to patients, as it reviews the potential cancer risk from the discovery of a carcinogen in the popular stomach pills.

Memorial Sloan Kettering Cancer Center is removing Zantac products from the list of drugs that it offers patients “out of caution due to a recent product alert from the Food and Drug Administration,” Caitlin Hool, a spokeswoman for the New York-based center, said in an email on Monday. The process will take a few weeks, she said.